 Connection
Wells Messersmith to Receptors, Enterotoxin
This is a "connection" page, showing publications Wells Messersmith has written about Receptors, Enterotoxin.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.173 |
|
|
|
-
Almhanna K, Miron ML, Wright D, Gracian AC, Hubner RA, Van Laethem JL, L?pez CM, Alsina M, Mu?oz FL, Bendell J, Firdaus I, Messersmith W, Ye Z, Fasanmade AA, Danaee H, Kalebic T. Phase II study of the antibody-drug conjugate TAK-264 (MLN0264) in patients with metastatic or recurrent adenocarcinoma of the stomach or gastroesophageal junction expressing guanylyl cyclase C. Invest New Drugs. 2017 04; 35(2):235-241.
Score: 0.138
-
Almhanna K, Wright D, Mercade TM, Van Laethem JL, Gracian AC, Guillen-Ponce C, Faris J, Lopez CM, Hubner RA, Bendell J, Bols A, Feliu J, Starling N, Enzinger P, Mahalingham D, Messersmith W, Yang H, Fasanmade A, Danaee H, Kalebic T. A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing guanylyl cyclase C. Invest New Drugs. 2017 10; 35(5):634-641.
Score: 0.035
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|